CM512 vs JNJ-95597528
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: TSLP + IL-13 · full Atopic Dermatitis pipeline
CM512
Developed by Belenos Biosciences under a licence from Keymed Biosciences
NCT06553209 · Phase 1 · completed
The study randomly assigned participants to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, its only defined goal was tracking adverse events rather than any measure of skin-disease improvement. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2027 · NCT07230483 (registry estimate)
Reported efficacy
Adverse events (Up to 141 days or up to 169 days): All treatment-related adverse events were Grade 1 or 2; no serious adverse events, no withdrawals for adverse events and no deaths. Pharmacokinetics were linear and dose-proportional from 150 to 1200 mg with a long terminal half-life (mean range 58.7 to 73.6 days). CM512 significantly reduced free TSLP and IL-13 and lowered blood eosinophils, IgE and TARC versus placebo.
Result source: NCT06553209
JNJ-95597528
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | CM512 | JNJ-95597528 |
|---|---|---|
| EASI-75 | —Not reported | —Not reported |
| IGA 0/1 with 2-point improvement | —Not reported | —Not reported |
| EASI-90 | —Not reported | —Not reported |
| EASI, % change | —Not reported | —Not reported |
EASI-75
- CM512
- —Not reported
- JNJ-95597528
- —Not reported
IGA 0/1 with 2-point improvement
- CM512
- —Not reported
- JNJ-95597528
- —Not reported
EASI-90
- CM512
- —Not reported
- JNJ-95597528
- —Not reported
EASI, % change
- CM512
- —Not reported
- JNJ-95597528
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CM512: no structured comparison results are available for Atopic Dermatitis.
JNJ-95597528: no structured comparison results are available for Atopic Dermatitis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM512's landscape · JNJ-95597528's landscape